Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triple Combination Therapy vs Combigan in Glaucoma/OHT
NCT01241240Phase 3Completed
- Sponsor
- Allergan
- Start
- Mar 2011
- Primary completion
- Sep 2013
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of bimatoprost in Open-angle glaucoma (OAG) and ocular hypertension (2 arms), sponsored by Allergan. Primary endpoint: Change From Baseline in Mean Worse Eye Intraocular Pressure (IOP) at Week 12. Started Mar 2011; status: completed.
02
Drugs
bimatoprost
03
Conditions
Open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on NCT01241240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01241240.